An observational study in Nontuberculous Mycobacterial Lung Disease and Mycobacterium Avium Complex (MAC), sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Eighth Affiliated Hospital, Sun Yat-sen University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Nontuberculous Mycobacterial lung disease (NTM-LD) is a significant infectious challenge. The precise causes remain unclear, diagnosis can be complex, treatment outcomes are often unsatisfactory, and the disease can severely affect a patient's quality of life. Environmental factors, such as the warm and humid climate in South China, may contribute to unique characteristics of NTM in this region, but systematic research is currently lacking.
This study aims to improve the understanding of NTM-LD in South China. It consists of two complementary parts:
The overall goal of this research is to generate evidence that can aid healthcare providers in South China in diagnosing and managing NTM-LD more effectively. Please note that this is an observational study; no new drugs or experimental treatments are being tested.
Study Objectives Primary Objective: To systematically characterize the epidemiological patterns, clinical phenotypes, and prognostic determinants of NTM-LD in the South China population.
Secondary Objectives:
To analyze the distribution of NTM species and their correlation with disease severity and radiological findings.
To investigate host immune microenvironment alterations post-NTM infection, focusing on inflammatory responses and immune cell functional states.
To explore molecular mechanisms associated with treatment refractoriness in NTM disease.
Study Design
This is a hybrid observational study comprising two distinct parts:
Study Populations and Sample Size
Methods and Procedures
Molecular Biology: Real-time quantitative PCR for cytokine expression profiling; Western blot for protein-level assessment.
Single-Cell Sequencing: To delineate immune cell composition, transcriptional states, and cell-cell interaction networks within the pulmonary immune microenvironment.
66 studies on the registry are indexed under Mycobacterium avium-intracellulare Infection; 8 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 50 across 11 observational studies indexed under Mycobacterium avium-intracellulare Infection.
Browse Mycobacterium avium-intracellulare Infection studies →Eighth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 10 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study population comprises patients diagnosed with nontuberculous mycobacterial infection in South China. It includes two nested cohorts: (1) a large multicenter retrospective cohort of approximately 1,500 patients identified from hospital records between 2015 and 2025, from whom clinical and epidemiological data will be extracted; and (2) a prospective sub-cohort of about 106 patients consecutively enrolled from the aforementioned group, who will provide additional biospecimens (peripheral blood and bronchoalveolar lavage fluid) for mechanistic laboratory investigations.
Inclusion Criteria:1. (Both Cohorts):
Available medical records covering the period from 2015 to 2025 (for the retrospective cohort).
2. (Prospective Sub-cohort Additional):
Exclusion Criteria: 1. (Both Cohorts):
Incomplete medical records that preclude adequate data extraction (for retrospective analysis).
2. (Prospective Sub-cohort Additional):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort consists of approximately 1,500 patients diagnosed with nontuberculous mycobacterial (NTM) across multiple hospitals in South China. Data, including demographics, clinical symptoms, imaging findings, microbiology results, and treatment outcomes, will be extracted retrospectively from electronic medical records for the period from January 2015 to May 2025.
Other: Prospective Biospecimen Sub-cohort
Observational
Clinical Phenotype Distribution
Proportion of patients with different clinical-radiological phenotypes of NTM-LD (nodular-bronchiectatic, fibrocavitary, hypersensitivity-like, and mixed patterns) based on chest CT imaging and clinical presentation.
Time frame: At time of diagnosis (assessed retrospectively from medical records between January 2015 and May 2025)
Treatment Response Categories
Distribution of treatment outcomes including: (1) microbiological conversion (negative cultures for ≥12 months), (2) treatment failure (persistent positive cultures despite appropriate therapy), (3) treatment intolerance requiring discontinuation, and (4) spontaneous improvement without treatment.
Time frame: 12 months post-diagnosis (assessed retrospectively from medical records between January 2015 and May 2025)
Spectrum of NTM Species
The spectrum and relative frequency of nontuberculous mycobacteria (NTM) species isolated from respiratory specimens (including sputum and bronchoalveolar lavage fluid) will be determined through retrospective analysis of positive culture and species identification results from the hospital's microbiology laboratory database. All patients with confirmed NTM pulmonary disease will be included in this analysis.
Time frame: Species distribution will be assessed at baseline, defined as the date of the first positive NTM culture from a respiratory specimen. Retrospective data collection will cover the period from January 2015 to May 2025.
Clinical Prognostic Factors
Specific clinical variables assessed for their association with treatment outcome. These include: presence of cavitation on baseline chest CT, body mass index (BMI) \< 18.5 kg/m² at diagnosis, CCI, NLR, NMLR, and a history of previous NTM treatment failure.
Time frame: Assessed at baseline (within 7 days of enrollment).
Immunological Prognostic Factors
Specific immunological variables assessed for their association with treatment outcome. This primarily refers to the presence and titer of neutralizing anti-interferon-gamma autoantibodies (nIFN-γ-autoAbs) in serum.
Time frame: Serum sample collected at baseline (within 7 days of enrollment) for antibody testing.
No study locations are listed for this record.
Plan to share: Yes — What data in particular will be shared? De-identified individual participant data that underlie the results reported in the primary publication (including baseline characteristics, primary and secondary outcome measures). What other documents will be available? Study protocol, statistical analysis plan, and informed consent form (if applicable). When will data be available (start and end dates)? • Beginning 1year after the publication of the primary results and ending 5 years thereafter. With whom? • Researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. For what types of analyses? For individual participant data meta-analysis or other secondary analyses approved by the proposal assessment committee. By what mechanism will data be made available? Proposals should be directed to [principal investigator's email address, jqzhang2002@126.com]. To gain access, requestors will need to sign a data access agreement. Data will be shared v
Supporting information: Study protocol
Time frame: Beginning 1year after the publication of the primary results and ending 5 years thereafter.
Access criteria: Access will be granted to external researchers (including individuals affiliated with academic institutions, healthcare organizations, or non-commercial research entities) who provide a methodologically sound research proposal that has received ethical approval (if applicable) from an institutional review board. The proposal must align with the original study's ethical framework and informed consent provisions. Proposals for commercial purposes will not be considered. Requestors may access the following de-identified datasets and documents: 1. Individual Participant Data: Key de-identified variables including demographics (age, gender), clinical characteristics (symptoms, imaging phenotypes, NTM species), laboratory results, and primary/secondary outcome measures. 2. Supporting Documents: The final approved study protocol, the statistical analysis plan, the informed consent form template, and the data dictionary defining all variables.
Data sharing details ↗ · www.icmje.org
Start is estimated for Jan 2026; primary completion for Jun 2028, 29 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mycobacterium avium-intracellulare Infection →
Eighth Affiliated Hospital, Sun Yat-sen University